Background Apremilast, an oral phosphodiesterase-4 inhibitor, has demonstrated efficacy in patients with moderate
Introduction LIBERATE (NCT01690299), a global phase 3b study in biologicnaive patients with moderate to severe plaque psoriasis, demonstrated that significantly more patients receiving apremilast for 16 weeks achieved PASI-75 (≥75% reduction from baseline in Psoriasis Area and Severity Index [PASI]) vs. placebo. 1 A post hoc analysis found no significant difference in response rates among patients given apremilast vs. etanercept, an anti-tumour necrosis factor-a biologic agent. 1 This report describes efficacy and safety outcomes from the LIBERATE apremilast-extension phase (Weeks 16-104) in patients who continued apremilast treatment through 104 weeks, including those who switched from etanercept or placebo.
Materials and methods

Patients and study design
Patient selection, study design and study methods have been described in detail. 1 Briefly, patients in the LIBERATE trial were adults in the United States, Canada, Europe (Belgium, Czech Republic, Estonia, Germany, Great Britain, Hungary, Latvia, the Netherlands) or Australia with chronic, moderate to severe plaque psoriasis with inadequate response, inability to tolerate or contraindication to treatment with ≥1 conventional systemic agent, and who were biologic-naive. Eligible patients were randomized (1 : 1 : 1) to double-blind treatment with apremilast 30 mg twice daily, etanercept subcutaneous injection 50 mg once weekly, or placebo for 16 weeks. At Week 16, placebo and etanercept patients were switched to apremilast (placebo, without titration; etanercept, with 1-week titration); apremilast patients continued apremilast treatment through Week 104.
Efficacy and safety assessments
The primary efficacy end point, the proportion of patients who achieved PASI-75 at Week 16, was previously reported. 
Statistical analysis
Efficacy analyses were performed in the modified intent-to-treat population (all randomized patients who received ≥1 dose of study medication and had baseline PASI and ≥1 post-treatment PASI assessments). Statistical analyses for between-group comparisons of efficacy assessments at Week 16 included CochranMantel-Haenszel tests for categorical variables and an analysis of covariance model for continuous variables. Efficacy assessments during the apremilast-extension phase were summarized using descriptive statistics at visits after treatment initiation. Missing values were imputed using last-observation-carried-forward (LOCF) methodology. Responder analyses of DLQI total score ≤5 and DLQI score of 0 or 1 were performed using data from completers without imputation. Safety was summarized using descriptive statistics. 1 
Results
Patients
There were 233 patients who completed the placebo-controlled phase among 250 randomized patients. There were 226 patients who entered the apremilast-extension phase (placebo/apremilast, n = 73; apremilast/apremilast, n = 74; etanercept/apremilast, n = 79); 138 (60.8%) completed the Week 104 visit. The most common reasons for withdrawal from the apremilast-extension phase were lack of efficacy (n = 27, 11.9%), lost to follow-up (n = 25, 11.0%) and withdrawal by patient (n = 24, 10.6%). Baseline characteristics were balanced between groups. 1 (Table 1) .
Other signs and symptoms of psoriasis that were significantly improved at Week 16 with apremilast vs. placebo included pruritus, scalp involvement and nail involvement ( Fig. 2a and 2b ). Improvements were maintained at Week 52 1 and Week 104 in patients who continued or were switched to . Missing values for improvements in scalp and nail psoriasis were imputed using LOCF methodology. The vertical lines indicate two-sided 95% confidence intervals. ScPGA response (0 [clear] or 1 [minimal]) examined among patients with ScPGA ≥3 (moderate or greater) at baseline; NAPSI examined among patients with NAPSI ≥1 at baseline; DLQI ≤5 examined among all patients who had data at time of observation (i.e. completers, without imputation; both P=NS vs. placebo at Week 16). DLQI, Dermatology Life Quality Index; LOCF, last observation carried forward; mITT, modified intent to treat; NAPSI, Nail Psoriasis Severity Index; ScPGA, Scalp Physician Global Assessment.
Safety
During the apremilast-extension phase, most AEs were mild or moderate in severity, and incidence of serious adverse events (SAEs) was similar across groups (Table 2) . Discontinuation rates due to AEs were generally low across groups during the apremilast-extension phase. No deaths occurred during the study. For AEs that occurred in ≥5% of patients during the placebo-controlled phase (diarrhoea, nausea, upper respiratory tract infection, nasopharyngitis, headache and tension headache 1 ), no increase in incidence was observed among patients in the apremilast/apremilast group with long-term exposure (Table 2) . No psychiatric AEs occurred in ≥5% of patients during the placebo-controlled phase or with long-term exposure in patients who continued or were switched to apremilast. 1 During the apremilast-extension phase, four patients in the apremilast/ apremilast group reported five psychiatric AEs (n = 1 [1.4%] each AE): anxiety, depression, insomnia, depressed mood and stress. Among placebo/apremilast or etanercept/apremilast patients, one in each group (1.4%, 1.3%, respectively) experienced an AE of depression, anxiety and insomnia. Among placebo/apremilast patients, psychotic disorder and suicidal ideation were experienced by one (1.4%) patient each; among etanercept/apremilast patients, two patients (2.5%) experienced altered mood. In patients reporting AEs of rebound psoriasis in the etanercept/apremilast group, the majority of events (five of seven) involved loss of PASI response after treatment was discontinued or completed, and no patients experienced worsening of PASI score ≥125% of baseline. All cases of diarrhoea and nausea occurring in the apremilastextension phase were mild or moderate in severity and generally resolved within 1 month. Of note, patients in the placebo/ apremilast group had no dose titration with apremilast at Week 16, which likely explains the higher incidence of diarrhoea in the placebo/apremilast group (17.8%) compared with incidence of diarrhoea with apremilast during the placebo-controlled phase (10.8%). 1 Marked laboratory abnormalities were infrequent and transient; incidence remained low across groups with continued apremilast treatment through 104 weeks. At Week 104, mean percentage change from baseline in bodyweight was À1.1% (placebo/apremilast), 0.21% (apremilast/apremilast) and À1.9% (etanercept/apremilast).
Discussion
Apremilast treatment in biologic-naive patients with moderate to severe psoriasis was effective and safe for up to 104 weeks, with improvements in skin, scalp, nails, pruritus and QOL. Efficacy and safety were maintained in patients who switched from etanercept to apremilast and remained in the study at Week 104. Patients also experienced minimal impact of psoriasis on QOL, with ≥66% of patients achieving DLQI ≤5 at Week 104. Improved QOL may help motivate patients to maintain treatment over time, which may lead to better disease control. The safety profile of apremilast during the apremilast-extension phase was consistent with the ESTEEM and PALACE trials. [2] [3] [4] [5] [6] [7] 
